SerenEx.com
Title
Welcome to Serenex.com
Description
Serenex is an integrated oncology-focused drug discovery and development company. Our mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care products. Our most advanced program, SNX-1012, is a product for chemotherapy and radiation-induced oral mucositis. This is scheduled to complete Phase II trials in Q4 2006. Our most advanced preclinical-stage program, SNX-5542, is a novel small molecule inhibitor of Heat Shock Protein 90. Hsp90 is a chaperone protein for a variety of oncogenic proteins (such as Her2 and Raf) and their downstream signaling molecules (such as Akt and Erk). SNX-5542 is scheduled to begin clinical trials in Q1 2007.
Our drug discovery is driven by a proprietary chemo-proteomics platform which enables us to understand complex interactions between a compound and multiple targets. We use the platform to profile compounds, in high throughput, against thousands of important therapeutic and toxicity targets simultaneously. By screening compounds in this manner we are able to better understand specificity and toxicity issues, drive structure-activity relationships (SAR) and help determine mechanism of action.
